Global Endometriosis Therapies Market

Endometriosis Therapies Comprehensive Study by Type (Hormonal Therapy (Oral Contraceptive Pills, Progestins), Hormone Replacement Therapy (GnRH Agonists, Luteinizing-hormone-releasing hormone receptor antagonist, etc.), Aromatase Inhibitors, Thermal Endometrial Ablation Devices), Application (Hospital, Clinic, Other), Drug Type (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, LNR-IUDs, Others), Synthetic Hormone (Danazol, Gestrinone), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, E-commerce), Surgery (Laparoscopy, Hysterectomy, Laparotomy), Treatment Type (Pain Management, Hormone Therapy) Players and Region - Global Market Outlook to 2030

Endometriosis Therapies Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Endometriosis Therapies
According to the endometriosis.org, the disorder, Endometriosis affects approximately one in 10 women during their reproductive years, estimating around 176 million women in the world. Endometriosis is a painful disorder in which the layer of tissue that normally surfaces inside the uterus, starts growing outside the uterus. This mainly occurs on the fallopian tubes, ovaries, and tissue around the uterus; however, in exceptional cases, it may occur in other parts of the body. Hormone therapies may be used as a treatment for mild endometriosis or as combined therapy, either before, or after surgery, for moderate to severe endometriosis. Further, High investment made by the Government in the R&D of endometriosis disorder and increasing female population of reproductive age is driving the Global Endometriosis Therapies market

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The Endometriosis therapies market is a consolidated market in terms of geography, where regions have a certain market share according to the awareness and adoption of endometriosis treatment. Countries, where proper healthcare infrastructure, routine awareness for self-hygiene, and women health initiatives are present, tend to deliver in the endometriosis treatment market. Moreover, Countries like The United States, Japan, United Kingdom, Germany, and Italy are estimated to contribute around 60% of the entire revenue from the endometriosis treatment market. This is primarily due to the awareness for endometriosis conditions present in these regions. Major players in the market are actively involved in clinical trials to develop novel treatment and diagnosis options to reduce the financial burden of the medical condition. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Endometriosis Therapies market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbVie Inc. (United States), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Bayer AG (Germany), Astellas Pharma, Inc. (Japan), Pfizer, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan) and Myovant Sciences (United Kingdom) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Meditrina Pharmaceuticals (Greece), Neurocrine Biosciences, Inc. (United States), Mayne Pharma Group Limited (Australia), Endoceutics, Inc.(Canada) and Evotec AG (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Endometriosis Therapies market by Type (Hormonal Therapy [Oral Contraceptive Pills, Progestins], Hormone Replacement Therapy [GnRH Agonists, Luteinizing-hormone-releasing hormone receptor antagonist, etc.], Aromatase Inhibitors and Thermal Endometrial Ablation Devices), Application (Hospital, Clinic and Other) and Region. On the basis of Type, Hormonal Therapy are dominating the market in the year 2023



On the basis of geography, the market of Endometriosis Therapies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by Drug Type, the sub-segment i.e. Oral Contraceptives will boost the Endometriosis Therapies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Synthetic Hormone, the sub-segment i.e. Danazol will boost the Endometriosis Therapies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Endometriosis Therapies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Surgery, the sub-segment i.e. Laparoscopy will boost the Endometriosis Therapies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment Type, the sub-segment i.e. Pain Management will boost the Endometriosis Therapies market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Availability of a Large Number of Branded as Well As Generic Products and Major Players in the Market Involved In Clinical Trials

Market Growth Drivers:
Increasing Female Population of the Reproductive Age, Availability of Various Treatment Options and Rising Prevalence of Endometriosis in Young Adults

Challenges:
The Paucity of Non-Invasive Diagnosis Test for the Disease and Limited Awareness and Understanding of Different Scales of Pain in Developed and Under-Developed Countries

Restraints:
High Cost of Advanced Therapeutic Drugs and Less Number of Studies On the Disease

Opportunities:
Increasing Efforts towards Drug Development and Therapies and Ongoing Different Clinical Trial Studies on Various Treatment Options

Market Leaders and their expansionary development strategies
In December 2023, Evotec, a leading drug discovery and development company, announced a strategic partnership with Gedeon Richter to develop novel therapies for endometriosis and other women's health conditions. This collaboration combines Evotec's drug discovery expertise with Gedeon Richter's experience in women's health to accelerate the development of promising new treatments.
December 20, 2023: AbbVie announces the US launch of Orlita (elagolix), the first and only once-daily oral GnRH antagonist approved for the treatment of endometriosis-associated moderate to severe pain. This launch offers a new non-surgical option for women suffering from endometriosis.
In July 2018, The FDA has approved Elagolix (Orilissa), the first drug developed for the treatment of moderate to severe pain from endometriosis. The drug has been manufactured by AbbVie Company. and The drug will offer a new therapy to some of the roughly 176 million women worldwide who experience the painful gynecological condition, many of whom suffer for years before finding an adequate therapy.

Key Target Audience
Endometriosis Therapy Manufacturers, Pharmaceutical Companies, Research Laboratories, Government and Regulatory Agencies, Potential Investors and Downstream Vendors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Hormonal Therapy [Oral Contraceptive Pills, Progestins]
  • Hormone Replacement Therapy [GnRH Agonists, Luteinizing-hormone-releasing hormone receptor antagonist, etc.]
  • Aromatase Inhibitors
  • Thermal Endometrial Ablation Devices
By Application
  • Hospital
  • Clinic
  • Other
By Drug Type
  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • LNR-IUDs
  • Others

By Synthetic Hormone
  • Danazol
  • Gestrinone

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-commerce

By Surgery
  • Laparoscopy
  • Hysterectomy
  • Laparotomy

By Treatment Type
  • Pain Management
  • Hormone Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Female Population of the Reproductive Age
      • 3.2.2. Availability of Various Treatment Options
      • 3.2.3. Rising Prevalence of Endometriosis in Young Adults
    • 3.3. Market Challenges
      • 3.3.1. The Paucity of Non-Invasive Diagnosis Test for the Disease
      • 3.3.2. Limited Awareness and Understanding of Different Scales of Pain in Developed and Under-Developed Countries
    • 3.4. Market Trends
      • 3.4.1. Availability of a Large Number of Branded as Well As Generic Products
      • 3.4.2. Major Players in the Market Involved In Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Endometriosis Therapies, by Type, Application, Drug Type, Synthetic Hormone, Distribution Channel, Surgery, Treatment Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Endometriosis Therapies (Value)
      • 5.2.1. Global Endometriosis Therapies by: Type (Value)
        • 5.2.1.1. Hormonal Therapy [Oral Contraceptive Pills, Progestins]
        • 5.2.1.2. Hormone Replacement Therapy [GnRH Agonists, Luteinizing-hormone-releasing hormone receptor antagonist, etc.]
        • 5.2.1.3. Aromatase Inhibitors
        • 5.2.1.4. Thermal Endometrial Ablation Devices
      • 5.2.2. Global Endometriosis Therapies by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Other
      • 5.2.3. Global Endometriosis Therapies by: Drug Type (Value)
        • 5.2.3.1. Oral Contraceptives
        • 5.2.3.2. Progestins
        • 5.2.3.3. NSAIDs
        • 5.2.3.4. GnRH Analogues
        • 5.2.3.5. LNR-IUDs
        • 5.2.3.6. Others
      • 5.2.4. Global Endometriosis Therapies by: Synthetic Hormone (Value)
        • 5.2.4.1. Danazol
        • 5.2.4.2. Gestrinone
      • 5.2.5. Global Endometriosis Therapies by: Distribution Channel (Value)
        • 5.2.5.1. Hospital Pharmacies
        • 5.2.5.2. Retail Pharmacies
        • 5.2.5.3. Drug Stores
        • 5.2.5.4. E-commerce
      • 5.2.6. Global Endometriosis Therapies by: Surgery (Value)
        • 5.2.6.1. Laparoscopy
        • 5.2.6.2. Hysterectomy
        • 5.2.6.3. Laparotomy
      • 5.2.7. Global Endometriosis Therapies by: Treatment Type (Value)
        • 5.2.7.1. Pain Management
        • 5.2.7.2. Hormone Therapy
      • 5.2.8. Global Endometriosis Therapies Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
  • 6. Endometriosis Therapies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Astellas Pharma, Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Myovant Sciences (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Endometriosis Therapies Sale, by Type, Application, Drug Type, Synthetic Hormone, Distribution Channel, Surgery, Treatment Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Endometriosis Therapies (Value)
      • 7.2.1. Global Endometriosis Therapies by: Type (Value)
        • 7.2.1.1. Hormonal Therapy [Oral Contraceptive Pills, Progestins]
        • 7.2.1.2. Hormone Replacement Therapy [GnRH Agonists, Luteinizing-hormone-releasing hormone receptor antagonist, etc.]
        • 7.2.1.3. Aromatase Inhibitors
        • 7.2.1.4. Thermal Endometrial Ablation Devices
      • 7.2.2. Global Endometriosis Therapies by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Other
      • 7.2.3. Global Endometriosis Therapies by: Drug Type (Value)
        • 7.2.3.1. Oral Contraceptives
        • 7.2.3.2. Progestins
        • 7.2.3.3. NSAIDs
        • 7.2.3.4. GnRH Analogues
        • 7.2.3.5. LNR-IUDs
        • 7.2.3.6. Others
      • 7.2.4. Global Endometriosis Therapies by: Synthetic Hormone (Value)
        • 7.2.4.1. Danazol
        • 7.2.4.2. Gestrinone
      • 7.2.5. Global Endometriosis Therapies by: Distribution Channel (Value)
        • 7.2.5.1. Hospital Pharmacies
        • 7.2.5.2. Retail Pharmacies
        • 7.2.5.3. Drug Stores
        • 7.2.5.4. E-commerce
      • 7.2.6. Global Endometriosis Therapies by: Surgery (Value)
        • 7.2.6.1. Laparoscopy
        • 7.2.6.2. Hysterectomy
        • 7.2.6.3. Laparotomy
      • 7.2.7. Global Endometriosis Therapies by: Treatment Type (Value)
        • 7.2.7.1. Pain Management
        • 7.2.7.2. Hormone Therapy
      • 7.2.8. Global Endometriosis Therapies Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Endometriosis Therapies: by Type(USD Million)
  • Table 2. Endometriosis Therapies Hormonal Therapy [Oral Contraceptive Pills, Progestins] , by Region USD Million (2018-2023)
  • Table 3. Endometriosis Therapies Hormone Replacement Therapy [GnRH Agonists, Luteinizing-hormone-releasing hormone receptor antagonist, etc.] , by Region USD Million (2018-2023)
  • Table 4. Endometriosis Therapies Aromatase Inhibitors , by Region USD Million (2018-2023)
  • Table 5. Endometriosis Therapies Thermal Endometrial Ablation Devices , by Region USD Million (2018-2023)
  • Table 6. Endometriosis Therapies: by Application(USD Million)
  • Table 7. Endometriosis Therapies Hospital , by Region USD Million (2018-2023)
  • Table 8. Endometriosis Therapies Clinic , by Region USD Million (2018-2023)
  • Table 9. Endometriosis Therapies Other , by Region USD Million (2018-2023)
  • Table 10. Endometriosis Therapies: by Drug Type(USD Million)
  • Table 11. Endometriosis Therapies Oral Contraceptives , by Region USD Million (2018-2023)
  • Table 12. Endometriosis Therapies Progestins , by Region USD Million (2018-2023)
  • Table 13. Endometriosis Therapies NSAIDs , by Region USD Million (2018-2023)
  • Table 14. Endometriosis Therapies GnRH Analogues , by Region USD Million (2018-2023)
  • Table 15. Endometriosis Therapies LNR-IUDs , by Region USD Million (2018-2023)
  • Table 16. Endometriosis Therapies Others , by Region USD Million (2018-2023)
  • Table 17. Endometriosis Therapies: by Synthetic Hormone(USD Million)
  • Table 18. Endometriosis Therapies Danazol , by Region USD Million (2018-2023)
  • Table 19. Endometriosis Therapies Gestrinone , by Region USD Million (2018-2023)
  • Table 20. Endometriosis Therapies: by Distribution Channel(USD Million)
  • Table 21. Endometriosis Therapies Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 22. Endometriosis Therapies Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 23. Endometriosis Therapies Drug Stores , by Region USD Million (2018-2023)
  • Table 24. Endometriosis Therapies E-commerce , by Region USD Million (2018-2023)
  • Table 25. Endometriosis Therapies: by Surgery(USD Million)
  • Table 26. Endometriosis Therapies Laparoscopy , by Region USD Million (2018-2023)
  • Table 27. Endometriosis Therapies Hysterectomy , by Region USD Million (2018-2023)
  • Table 28. Endometriosis Therapies Laparotomy , by Region USD Million (2018-2023)
  • Table 29. Endometriosis Therapies: by Treatment Type(USD Million)
  • Table 30. Endometriosis Therapies Pain Management , by Region USD Million (2018-2023)
  • Table 31. Endometriosis Therapies Hormone Therapy , by Region USD Million (2018-2023)
  • Table 32. South America Endometriosis Therapies, by Country USD Million (2018-2023)
  • Table 33. South America Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 34. South America Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 35. South America Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 36. South America Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 37. South America Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 38. South America Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 39. South America Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 40. Brazil Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 41. Brazil Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 42. Brazil Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 43. Brazil Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 44. Brazil Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 45. Brazil Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 46. Brazil Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 47. Argentina Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 48. Argentina Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 49. Argentina Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 50. Argentina Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 51. Argentina Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 52. Argentina Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 53. Argentina Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 54. Rest of South America Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 55. Rest of South America Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 56. Rest of South America Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 57. Rest of South America Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 58. Rest of South America Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 59. Rest of South America Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 60. Rest of South America Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 61. Asia Pacific Endometriosis Therapies, by Country USD Million (2018-2023)
  • Table 62. Asia Pacific Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 63. Asia Pacific Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 64. Asia Pacific Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 65. Asia Pacific Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 66. Asia Pacific Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 67. Asia Pacific Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 68. Asia Pacific Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 69. China Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 70. China Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 71. China Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 72. China Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 73. China Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 74. China Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 75. China Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 76. Japan Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 77. Japan Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 78. Japan Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 79. Japan Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 80. Japan Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 81. Japan Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 82. Japan Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 83. India Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 84. India Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 85. India Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 86. India Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 87. India Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 88. India Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 89. India Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 90. South Korea Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 91. South Korea Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 92. South Korea Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 93. South Korea Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 94. South Korea Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 95. South Korea Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 96. South Korea Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 97. Taiwan Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 98. Taiwan Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 99. Taiwan Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 100. Taiwan Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 101. Taiwan Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 102. Taiwan Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 103. Taiwan Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 104. Australia Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 105. Australia Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 106. Australia Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 107. Australia Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 108. Australia Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 109. Australia Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 110. Australia Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 111. Rest of Asia-Pacific Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 112. Rest of Asia-Pacific Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 113. Rest of Asia-Pacific Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 114. Rest of Asia-Pacific Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 115. Rest of Asia-Pacific Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 116. Rest of Asia-Pacific Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 117. Rest of Asia-Pacific Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 118. Europe Endometriosis Therapies, by Country USD Million (2018-2023)
  • Table 119. Europe Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 120. Europe Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 121. Europe Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 122. Europe Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 123. Europe Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 124. Europe Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 125. Europe Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 126. Germany Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 127. Germany Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 128. Germany Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 129. Germany Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 130. Germany Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 131. Germany Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 132. Germany Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 133. France Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 134. France Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 135. France Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 136. France Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 137. France Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 138. France Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 139. France Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 140. Italy Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 141. Italy Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 142. Italy Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 143. Italy Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 144. Italy Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 145. Italy Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 146. Italy Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 147. United Kingdom Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 148. United Kingdom Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 149. United Kingdom Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 150. United Kingdom Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 151. United Kingdom Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 152. United Kingdom Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 153. United Kingdom Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 154. Netherlands Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 155. Netherlands Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 156. Netherlands Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 157. Netherlands Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 158. Netherlands Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 159. Netherlands Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 160. Netherlands Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 161. Rest of Europe Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 162. Rest of Europe Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 163. Rest of Europe Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 164. Rest of Europe Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 165. Rest of Europe Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 166. Rest of Europe Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 167. Rest of Europe Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 168. MEA Endometriosis Therapies, by Country USD Million (2018-2023)
  • Table 169. MEA Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 170. MEA Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 171. MEA Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 172. MEA Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 173. MEA Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 174. MEA Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 175. MEA Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 176. Middle East Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 177. Middle East Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 178. Middle East Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 179. Middle East Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 180. Middle East Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 181. Middle East Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 182. Middle East Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 183. Africa Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 184. Africa Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 185. Africa Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 186. Africa Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 187. Africa Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 188. Africa Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 189. Africa Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 190. North America Endometriosis Therapies, by Country USD Million (2018-2023)
  • Table 191. North America Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 192. North America Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 193. North America Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 194. North America Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 195. North America Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 196. North America Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 197. North America Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 198. United States Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 199. United States Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 200. United States Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 201. United States Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 202. United States Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 203. United States Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 204. United States Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 205. Canada Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 206. Canada Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 207. Canada Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 208. Canada Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 209. Canada Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 210. Canada Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 211. Canada Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 212. Mexico Endometriosis Therapies, by Type USD Million (2018-2023)
  • Table 213. Mexico Endometriosis Therapies, by Application USD Million (2018-2023)
  • Table 214. Mexico Endometriosis Therapies, by Drug Type USD Million (2018-2023)
  • Table 215. Mexico Endometriosis Therapies, by Synthetic Hormone USD Million (2018-2023)
  • Table 216. Mexico Endometriosis Therapies, by Distribution Channel USD Million (2018-2023)
  • Table 217. Mexico Endometriosis Therapies, by Surgery USD Million (2018-2023)
  • Table 218. Mexico Endometriosis Therapies, by Treatment Type USD Million (2018-2023)
  • Table 219. Company Basic Information, Sales Area and Its Competitors
  • Table 220. Company Basic Information, Sales Area and Its Competitors
  • Table 221. Company Basic Information, Sales Area and Its Competitors
  • Table 222. Company Basic Information, Sales Area and Its Competitors
  • Table 223. Company Basic Information, Sales Area and Its Competitors
  • Table 224. Company Basic Information, Sales Area and Its Competitors
  • Table 225. Company Basic Information, Sales Area and Its Competitors
  • Table 226. Company Basic Information, Sales Area and Its Competitors
  • Table 227. Endometriosis Therapies: by Type(USD Million)
  • Table 228. Endometriosis Therapies Hormonal Therapy [Oral Contraceptive Pills, Progestins] , by Region USD Million (2025-2030)
  • Table 229. Endometriosis Therapies Hormone Replacement Therapy [GnRH Agonists, Luteinizing-hormone-releasing hormone receptor antagonist, etc.] , by Region USD Million (2025-2030)
  • Table 230. Endometriosis Therapies Aromatase Inhibitors , by Region USD Million (2025-2030)
  • Table 231. Endometriosis Therapies Thermal Endometrial Ablation Devices , by Region USD Million (2025-2030)
  • Table 232. Endometriosis Therapies: by Application(USD Million)
  • Table 233. Endometriosis Therapies Hospital , by Region USD Million (2025-2030)
  • Table 234. Endometriosis Therapies Clinic , by Region USD Million (2025-2030)
  • Table 235. Endometriosis Therapies Other , by Region USD Million (2025-2030)
  • Table 236. Endometriosis Therapies: by Drug Type(USD Million)
  • Table 237. Endometriosis Therapies Oral Contraceptives , by Region USD Million (2025-2030)
  • Table 238. Endometriosis Therapies Progestins , by Region USD Million (2025-2030)
  • Table 239. Endometriosis Therapies NSAIDs , by Region USD Million (2025-2030)
  • Table 240. Endometriosis Therapies GnRH Analogues , by Region USD Million (2025-2030)
  • Table 241. Endometriosis Therapies LNR-IUDs , by Region USD Million (2025-2030)
  • Table 242. Endometriosis Therapies Others , by Region USD Million (2025-2030)
  • Table 243. Endometriosis Therapies: by Synthetic Hormone(USD Million)
  • Table 244. Endometriosis Therapies Danazol , by Region USD Million (2025-2030)
  • Table 245. Endometriosis Therapies Gestrinone , by Region USD Million (2025-2030)
  • Table 246. Endometriosis Therapies: by Distribution Channel(USD Million)
  • Table 247. Endometriosis Therapies Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 248. Endometriosis Therapies Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 249. Endometriosis Therapies Drug Stores , by Region USD Million (2025-2030)
  • Table 250. Endometriosis Therapies E-commerce , by Region USD Million (2025-2030)
  • Table 251. Endometriosis Therapies: by Surgery(USD Million)
  • Table 252. Endometriosis Therapies Laparoscopy , by Region USD Million (2025-2030)
  • Table 253. Endometriosis Therapies Hysterectomy , by Region USD Million (2025-2030)
  • Table 254. Endometriosis Therapies Laparotomy , by Region USD Million (2025-2030)
  • Table 255. Endometriosis Therapies: by Treatment Type(USD Million)
  • Table 256. Endometriosis Therapies Pain Management , by Region USD Million (2025-2030)
  • Table 257. Endometriosis Therapies Hormone Therapy , by Region USD Million (2025-2030)
  • Table 258. South America Endometriosis Therapies, by Country USD Million (2025-2030)
  • Table 259. South America Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 260. South America Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 261. South America Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 262. South America Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 263. South America Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 264. South America Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 265. South America Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 266. Brazil Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 267. Brazil Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 268. Brazil Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 269. Brazil Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 270. Brazil Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 271. Brazil Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 272. Brazil Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 273. Argentina Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 274. Argentina Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 275. Argentina Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 276. Argentina Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 277. Argentina Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 278. Argentina Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 279. Argentina Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 280. Rest of South America Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 281. Rest of South America Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 282. Rest of South America Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 283. Rest of South America Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 284. Rest of South America Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 285. Rest of South America Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 286. Rest of South America Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 287. Asia Pacific Endometriosis Therapies, by Country USD Million (2025-2030)
  • Table 288. Asia Pacific Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 289. Asia Pacific Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 290. Asia Pacific Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 291. Asia Pacific Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 292. Asia Pacific Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 293. Asia Pacific Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 294. Asia Pacific Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 295. China Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 296. China Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 297. China Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 298. China Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 299. China Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 300. China Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 301. China Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 302. Japan Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 303. Japan Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 304. Japan Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 305. Japan Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 306. Japan Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 307. Japan Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 308. Japan Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 309. India Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 310. India Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 311. India Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 312. India Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 313. India Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 314. India Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 315. India Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 316. South Korea Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 317. South Korea Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 318. South Korea Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 319. South Korea Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 320. South Korea Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 321. South Korea Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 322. South Korea Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 323. Taiwan Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 324. Taiwan Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 325. Taiwan Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 326. Taiwan Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 327. Taiwan Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 328. Taiwan Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 329. Taiwan Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 330. Australia Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 331. Australia Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 332. Australia Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 333. Australia Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 334. Australia Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 335. Australia Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 336. Australia Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 337. Rest of Asia-Pacific Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 338. Rest of Asia-Pacific Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 339. Rest of Asia-Pacific Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 340. Rest of Asia-Pacific Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 341. Rest of Asia-Pacific Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 342. Rest of Asia-Pacific Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 343. Rest of Asia-Pacific Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 344. Europe Endometriosis Therapies, by Country USD Million (2025-2030)
  • Table 345. Europe Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 346. Europe Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 347. Europe Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 348. Europe Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 349. Europe Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 350. Europe Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 351. Europe Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 352. Germany Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 353. Germany Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 354. Germany Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 355. Germany Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 356. Germany Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 357. Germany Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 358. Germany Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 359. France Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 360. France Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 361. France Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 362. France Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 363. France Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 364. France Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 365. France Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 366. Italy Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 367. Italy Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 368. Italy Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 369. Italy Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 370. Italy Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 371. Italy Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 372. Italy Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 373. United Kingdom Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 374. United Kingdom Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 375. United Kingdom Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 376. United Kingdom Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 377. United Kingdom Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 378. United Kingdom Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 379. United Kingdom Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 380. Netherlands Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 381. Netherlands Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 382. Netherlands Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 383. Netherlands Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 384. Netherlands Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 385. Netherlands Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 386. Netherlands Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 387. Rest of Europe Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 388. Rest of Europe Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 389. Rest of Europe Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 390. Rest of Europe Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 391. Rest of Europe Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 392. Rest of Europe Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 393. Rest of Europe Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 394. MEA Endometriosis Therapies, by Country USD Million (2025-2030)
  • Table 395. MEA Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 396. MEA Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 397. MEA Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 398. MEA Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 399. MEA Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 400. MEA Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 401. MEA Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 402. Middle East Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 403. Middle East Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 404. Middle East Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 405. Middle East Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 406. Middle East Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 407. Middle East Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 408. Middle East Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 409. Africa Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 410. Africa Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 411. Africa Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 412. Africa Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 413. Africa Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 414. Africa Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 415. Africa Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 416. North America Endometriosis Therapies, by Country USD Million (2025-2030)
  • Table 417. North America Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 418. North America Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 419. North America Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 420. North America Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 421. North America Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 422. North America Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 423. North America Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 424. United States Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 425. United States Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 426. United States Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 427. United States Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 428. United States Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 429. United States Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 430. United States Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 431. Canada Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 432. Canada Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 433. Canada Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 434. Canada Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 435. Canada Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 436. Canada Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 437. Canada Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 438. Mexico Endometriosis Therapies, by Type USD Million (2025-2030)
  • Table 439. Mexico Endometriosis Therapies, by Application USD Million (2025-2030)
  • Table 440. Mexico Endometriosis Therapies, by Drug Type USD Million (2025-2030)
  • Table 441. Mexico Endometriosis Therapies, by Synthetic Hormone USD Million (2025-2030)
  • Table 442. Mexico Endometriosis Therapies, by Distribution Channel USD Million (2025-2030)
  • Table 443. Mexico Endometriosis Therapies, by Surgery USD Million (2025-2030)
  • Table 444. Mexico Endometriosis Therapies, by Treatment Type USD Million (2025-2030)
  • Table 445. Research Programs/Design for This Report
  • Table 446. Key Data Information from Secondary Sources
  • Table 447. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Endometriosis Therapies: by Type USD Million (2018-2023)
  • Figure 5. Global Endometriosis Therapies: by Application USD Million (2018-2023)
  • Figure 6. Global Endometriosis Therapies: by Drug Type USD Million (2018-2023)
  • Figure 7. Global Endometriosis Therapies: by Synthetic Hormone USD Million (2018-2023)
  • Figure 8. Global Endometriosis Therapies: by Distribution Channel USD Million (2018-2023)
  • Figure 9. Global Endometriosis Therapies: by Surgery USD Million (2018-2023)
  • Figure 10. Global Endometriosis Therapies: by Treatment Type USD Million (2018-2023)
  • Figure 11. South America Endometriosis Therapies Share (%), by Country
  • Figure 12. Asia Pacific Endometriosis Therapies Share (%), by Country
  • Figure 13. Europe Endometriosis Therapies Share (%), by Country
  • Figure 14. MEA Endometriosis Therapies Share (%), by Country
  • Figure 15. North America Endometriosis Therapies Share (%), by Country
  • Figure 16. Global Endometriosis Therapies share by Players 2023 (%)
  • Figure 17. Global Endometriosis Therapies share by Players (Top 3) 2023(%)
  • Figure 18. Global Endometriosis Therapies share by Players (Top 5) 2023(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 23. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 24. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 26. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 28. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2023
  • Figure 30. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 34. Myovant Sciences (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Myovant Sciences (United Kingdom) Revenue: by Geography 2023
  • Figure 36. Global Endometriosis Therapies: by Type USD Million (2025-2030)
  • Figure 37. Global Endometriosis Therapies: by Application USD Million (2025-2030)
  • Figure 38. Global Endometriosis Therapies: by Drug Type USD Million (2025-2030)
  • Figure 39. Global Endometriosis Therapies: by Synthetic Hormone USD Million (2025-2030)
  • Figure 40. Global Endometriosis Therapies: by Distribution Channel USD Million (2025-2030)
  • Figure 41. Global Endometriosis Therapies: by Surgery USD Million (2025-2030)
  • Figure 42. Global Endometriosis Therapies: by Treatment Type USD Million (2025-2030)
  • Figure 43. South America Endometriosis Therapies Share (%), by Country
  • Figure 44. Asia Pacific Endometriosis Therapies Share (%), by Country
  • Figure 45. Europe Endometriosis Therapies Share (%), by Country
  • Figure 46. MEA Endometriosis Therapies Share (%), by Country
  • Figure 47. North America Endometriosis Therapies Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Eli Lilly and Company (United States)
  • AstraZeneca (United Kingdom)
  • Bayer AG (Germany)
  • Astellas Pharma, Inc. (Japan)
  • Pfizer, Inc. (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Myovant Sciences (United Kingdom)
Additional players considered in the study are as follows:
Meditrina Pharmaceuticals (Greece) , Neurocrine Biosciences, Inc. (United States) , Mayne Pharma Group Limited (Australia) , Endoceutics, Inc.(Canada) , Evotec AG (Germany)
Select User Access Type

Key Highlights of Report


Jan 2024 221 Pages 89 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Endometriosis Therapies Market Quantitative research analysis
Global Endometriosis Therapies Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbVie Inc. (United States), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Bayer AG (Germany), Astellas Pharma, Inc. (Japan), Pfizer, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan) and Myovant Sciences (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Availability of a Large Number of Branded as Well As Generic Products " is seen as one of major influencing trends for Endometriosis Therapies Market during projected period 2023-2030.
The Endometriosis Therapies market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Endometriosis Therapies Market Report?

Have a Query? Click Here

Other Related Reports

Thyroid Gland Disorder Treatment Comprehensive Study by Type (Medication, Surgery), Application (Men, Women), Diagnosis (Blood Tests, Imaging Tests, Physical Exams), Disorder Type (Hypothyroidism, Hy...
$ 3450
Lumbar Spine Fusion Comprehensive Study by Type (Anterior lumbar interbody fusion, Lateral lumbar interbody fusion, Posterior lumbar interbody fusion, Others), Application (Hospitals, Ambulatory Surg...
$ 3750
Liver Cirrhosis Comprehensive Study by Type (Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis, Cardiac Cirrhosis, Cryptogenic Cirrhosis), Application (Hospitals, Specialty Clinics, Others),...
$ 3750
Simvastatin Comprehensive Study by Type (Enzymatic Synthesis, Chemical Synthesis), Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Form type (Tablet, Capsule) Players and Region - ...
$ 3500
Actinic Keratosis Treatment Comprehensive Study by Type (Flurouracil cream, Imiquimod cream, Ingenol Mebutate Gel, Diclofenac Gel), Application (Topical Surgery, Photodynamic Therapy, Other), Distrib...
$ 3450
Bladder Cancer Therapeutics Comprehensive Study by Type (Surgery, Chemotherapy, Immunotherapy, Radiation Therapy), Application (Hospitals, Specialty Clinics, Others), Tests Type (Cystoscopy, Biopsy, ...
$ 3750